The STAU1-CD44v8-10 axis regulates the initiation and progression of lung squamous cell carcinoma through PI3K/AKT signaling

Lung squamous cell carcinoma is a serious form of lung cancer that often begins in the lining of the airways. It is strongly linked to smoking, and while modern medicine has made strides in treating advanced cases, the earliest steps that turn a healthy cell into a cancerous one remain a mystery. Scientists have long known that cells in our bodies carry instructions written in a code called DNA. To use these instructions, the cell first copies them into a working molecule called RNA. However, the cell does not always read these instructions exactly as written. It often edits them, cutting out certain sections and pasting others together in different combinations. This process, known as alternative splicing, allows a single gene to produce many different versions of a protein, much like a single recipe yielding different dishes depending on which ingredients are added or skipped. In cancer, this editing process often goes wrong, creating abnormal protein versions that help tumors grow and spread. Understanding exactly which of these abnormal versions drives the disease could reveal new ways to stop it before it becomes deadly.

A team of researchers at Guangzhou Medical University and other institutions has now identified a specific culprit in this process for lung squamous cell carcinoma. They focused on a protein called CD44, which sits on the surface of cells and helps them stick to their surroundings. While the standard version of this protein exists in healthy tissues, cancer cells often produce a modified version called CD44v8-10. The researchers found that this specific variant is far more common in lung squamous cell carcinoma tumors than in healthy lung tissue. When they looked at patient records, they discovered that people with higher levels of this variant tended to have worse outcomes, suggesting it plays a key role in the disease's aggression.

To understand what this variant actually does, the scientists turned to cell cultures in the lab. They took normal human lung cells that had not yet become cancerous and forced them to produce extra amounts of the CD44v8-10 variant. The result was immediate and dramatic: these once-healthy cells began to behave like cancer. They started dividing much faster, ignored the usual signals to stop growing, and began to move and invade other areas, a trait known as metastasis. The researchers traced this behavior to a specific internal signaling pathway, a chain of chemical messages that tells the cell to grow. They found that the CD44v8-10 variant acted like a switch, flipping this growth pathway on. When they blocked this pathway with drugs, the abnormal growth stopped, confirming that the variant was the driver.

The team also investigated how this variant gets turned on in the first place. They discovered that a protein called STAU1 acts as the master regulator. In healthy cells, STAU1 helps manage the editing of RNA, but in the cancer cells they studied, STAU1 levels were unusually high. This excess STAU1 seemed to instruct the cell to produce the CD44v8-10 variant instead of the normal version. When the researchers reduced the amount of STAU1 in the cancer cells, the production of the harmful variant dropped, and the cells slowed down their growth. This suggested a clear chain of command: high STAU1 leads to high CD44v8-10, which in turn triggers the aggressive growth of the tumor.

To see if this held true in a living system, the researchers tested their findings in mice. They implanted human lung cancer cells into the animals and waited for small tumors to form. Once the tumors were established, they injected a treatment designed to silence the CD44v8-10 variant directly into the tumors. The results were striking. The treated tumors stopped growing and were significantly smaller than those in the control group, which received a harmless injection. The mice remained healthy throughout the experiment, indicating that targeting this specific variant did not harm the animals. The researchers also looked at the effect of cigarette smoke, a known cause of this cancer. They exposed normal lung cells to a liquid extract of cigarette smoke, which caused the cells to produce more of the CD44v8-10 variant and begin to grow uncontrollably. When they blocked the variant in these smoke-exposed cells, the harmful effects were reversed, suggesting that the variant is a critical link between smoking and the start of the disease.

The study concludes that the STAU1-CD44v8-10 axis is a powerful engine driving the initiation and progression of lung squamous cell carcinoma. By keeping the growth signals permanently active, this mechanism allows cancer cells to divide rapidly and spread. While the researchers note that they still need to fully map out every molecular step of how the variant activates these signals, their work provides a clear target. It suggests that therapies designed to block either the STAU1 regulator or the CD44v8-10 variant itself could potentially stop the cancer before it takes hold or slow its growth once it has started. This discovery shifts the focus from looking at the cancer as a whole to targeting the specific, abnormal version of a protein that makes it dangerous, offering a new path for early intervention and treatment.